FRANKLIN, Mass., Feb. 5 Echo Therapeutics, Inc.(OTC Bulletin Board: ECTE), a specialty pharmaceuticals and diabetesmanagement company, announced today that Patrick T. Mooney, M.D, Chairman andChief Executive Officer, will present at the RedChip Small-Cap InvestorConference on February 7, 2008 at 3:50 pm Mountain Standard Time (5:50 pmEastern Standard Time). The conference will be held at the Four SeasonsResort in Scottsdale, Arizona. A live video webcast of the presentation willbe available on the RedChip Small-Cap Investor Conference website,http://www.visualwebcaster.com/RedChipfeb2008/. A replay of the webcast andthe corresponding presentation will be available on Echo Therapeutics' websiteshortly following the live presentation.
About Echo Therapeutics
Echo Therapeutics is a platform-enabled, specialty pharmaceuticals anddiabetes management company leveraging its expertise in transdermal science todevelop and commercialize non-invasive specialty pharmaceutical products andmedical devices. Echo's Symphony(TM) CTGM System is a next generation needle-free, wireless, continuous transdermal glucose monitoring (CTGM) system fordiabetes home use and emerging hospital critical care markets. Symphony isdesigned to provide on-demand glucose data conveniently, continuously andcost-effectively. Symphony incorporates Echo's patented feedback mechanism foroptimal skin permeation control and its continuous transdermal biosensor. WithSymphony, Echo is focused on changing the paradigm of invasive, episodicglucose testing in diabetes home use and hospital critical care settings. Echois also marshalling the potential of its patented AzoneTS(TM) transdermal drugdelivery technology to build an extensive pipeline of advanced topicalreformulations of FDA-approved products in accordance with the FDA's Section505(b)(2) guidelines. Echo has submitted a New Drug Application (NDA) to theFDA for the approval of its lead AzoneTS-based product candidate,Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.
This press release contains forward-looking information that involvesrisks and uncertainties, including statements regarding Echo's developmentplans, objectives, expectations and intentions, including, without limitation,statements regarding the Company's Symphony and AzoneTS product candidates.Factors that could adversely affect Echo's business and prospects aredescribed in the Company's filings with the Securities and ExchangeCommission. Echo expressly disclaims any obligation or undertaking to releasepublicly any updates or revisions to any such statements to reflect any changein the Company's expectations or any change in events, conditions orcircumstances on which any such statement is based.Investor Relations Contacts: Patrick T. Mooney, M.D. Chairman & CEO Echo Therapeutics 508-530-0329 Lilian Stern Stern Investor Relations 212-362-1200
SOURCE Echo Therapeutics, Inc.